AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Join SI Premium – FREE
AbbVie (NYSE: ABBV) reported Q2 EPS of $3.65, $0.06 worse than the analyst estimate of $3.71. Revenue for the quarter came in at $16.99 billion versus the consensus estimate of $16.77 billion.
GUIDANCE:
AbbVie sees FY2026 EPS of $13.87-$14.07, versus the consensus of $14.12.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Customers Bancorp (CUBI) Tops Q3 EPS by 11c
- Avidia Bancorp, Inc. (AVBC) Tops Q3 EPS by 16c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
